SHANGHAI, July 23, 2026
ArkBio has successfully completed dosing across all cohorts in its Australian Phase I clinical trial evaluating AK0406, an investigational long-acting antiviral-Fc conjugate (AFC) therapy designed for influenza prophylaxis. The study has now advanced into the follow-up phase, marking an important milestone in the clinical development of the novel antiviral candidate. AK0406 has been engineered to provide long-lasting protection against influenza A and B viruses through a unique antibody Fc-conjugation technology that combines potent antiviral activity with extended circulation time. As seasonal influenza continues to pose a major global health burden despite available vaccines, ArkBio aims to develop an innovative therapy capable of delivering sustained pre- and post-exposure protection, particularly for populations at higher risk of infection or reduced vaccine effectiveness. The successful completion of Phase I dosing reflects continued progress in expanding the company’s respiratory disease pipeline while supporting the development of next-generation antiviral therapeutics.
AK0406 Designed to Deliver Long-Lasting Influenza Protection
AK0406 represents a new class of long-acting antiviral-Fc conjugate (AFC) medicines, created by precisely linking highly potent antiviral compounds to an antibody Fc fragment. This design enables the therapy to remain active in the body for an extended period while preserving important immune-mediated Fc functions that may enhance antiviral activity. According to ArkBio, preclinical studies demonstrated that AK0406 provides broad-spectrum activity against both influenza A and influenza B viruses, maintains strong antiviral potency, and delivers prolonged protection suitable for both pre-exposure and post-exposure prophylaxis. The therapy has also been optimized to achieve an improved pharmacological profile that could support future therapeutic use alongside preventive applications. By combining extended durability with targeted antiviral activity, AK0406 has the potential to overcome several limitations associated with current influenza prevention strategies.
Novel AFC Technology Addresses Influenza Prevention Challenges
Despite widespread seasonal vaccination programs, influenza remains one of the world’s most significant infectious diseases due to the continuous evolution of circulating viral strains. Annual vaccines often face challenges related to antigenic drift, strain-selection uncertainty, and lower effectiveness among elderly individuals, immunocompromised patients, and other vulnerable populations. ArkBio believes its AFC technology platform offers a promising alternative by providing sustained antiviral protection that is less dependent on seasonal strain prediction. The completion of all participant dosing in the Australian Phase I trial represents a key step toward evaluating the safety and tolerability of this innovative approach in healthy volunteers before progressing into later-stage clinical studies. If clinical development continues successfully, AK0406 could provide healthcare providers with a longer-lasting preventive option capable of reducing influenza transmission and disease burden across diverse patient populations.
Advertisement
ArkBio Strengthens Respiratory Disease Development Pipeline
The successful advancement of AK0406 further strengthens ArkBio’s growing portfolio of innovative therapies targeting respiratory, pulmonary, and pediatric diseases. Founded in 2014, the biotechnology company has established multiple proprietary research platforms while advancing several clinical-stage assets. Its pipeline includes ziresovir (AK0529) for respiratory syncytial virus (RSV), AK3280 for idiopathic pulmonary fibrosis, and AK0901, an approved treatment for pediatric and adult ADHD in China. ArkBio has also built strategic collaborations with leading pharmaceutical companies and research institutions to accelerate drug discovery and development. The completion of Phase I dosing for AK0406 demonstrates the company’s commitment to expanding innovative antiviral treatment options and addressing critical global public health challenges through next-generation biologic technologies that combine scientific innovation with improved patient outcomes.
Source: ArkBio press release
